BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 16907845)

  • 1. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion.
    Liu CJ; Chen PJ; Lai MY; Kao JH; Chen DS
    J Med Virol; 2004 Oct; 74(2):237-45. PubMed ID: 15332272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; GĂ©rolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
    Kim HJ; Yoo BC
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
    Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.
    Chan HL; Hussain M; Lok AS
    Hepatology; 1999 Mar; 29(3):976-84. PubMed ID: 10051506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants.
    Chowdhury A; Santra A; Chakravorty R; Banerji A; Pal S; Dhali GK; Datta S; Banerji S; Manna B; Chowdhury SR; Bhattacharya SK; Mazumder DG
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1712-20. PubMed ID: 16246191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
    Elkady A; Tanaka Y; Kurbanov F; Oynsuren T; Mizokami M
    J Gastroenterol Hepatol; 2008 Mar; 23(3):474-81. PubMed ID: 18318825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B.
    Loriot MA; Marcellin P; Talbodec N; Guigonis V; Gigou M; Boyer N; Bezeaud A; Erlinger S; Benhamou JP
    Hepatology; 1995 Mar; 21(3):627-31. PubMed ID: 7875659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
    Ferns RB; Naoumov NV; Gilson RJ; Tedder RS
    J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
    Sugauchi F; Tanaka Y; Kusumoto S; Matsuura K; Sugiyama M; Kurbanov F; Ueda R; Mizokami M
    J Med Virol; 2011 Mar; 83(3):412-8. PubMed ID: 21264861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis.
    Liu CJ; Kao JH; Lai MY; Chen PJ; Chen DS
    J Med Virol; 2004 Apr; 72(4):545-50. PubMed ID: 14981756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter.
    Yamaura T; Tanaka E; Matsumoto A; Rokuhara A; Orii K; Yoshizawa K; Miyakawa Y; Kiyosawa K
    J Med Virol; 2003 Aug; 70(4):545-52. PubMed ID: 12794716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients.
    Tsai MC; Chen CH; Lee CM; Chen YT; Chien YS; Hung CH; Wang JH; Lu SN; Yen YH; Changchien CS; Hu TH
    J Hepatol; 2009 Feb; 50(2):281-8. PubMed ID: 19070392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new core promoter mutation and premature stop codon in the S gene in HBV strains from Iranian patients with cirrhosis.
    Veazjalali M; Norder H; Magnius L; Jazayeri SM; Alavian SM; Mokhtari-Azad T
    J Viral Hepat; 2009 Apr; 16(4):259-64. PubMed ID: 19222745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.